GENE ONLINE|News &
Opinion
Blog

Market Insight on FDA-approvals: Rise of First-in-class and Regenerative Innovations

by GeneOnline
Share To
Achieving market entry for new drugs has never been more challenging,  especially for non-COVID medications during a time shrouded in COVID-19. Notably, the US FDA has pushed to accelerate the launches of non-COVID medications and has been reviewing more next-generation (Next-Gen) drugs in the last 14 months. Next-Gen drugs, here chiefly describing the first-in-class and regeneration ones which encompass strong clinical benefits and market competitions, are evolving fast year on year.

GO Prime with only $1.49 now

LATEST
OncoC4 Bags $200 Million In CTLA-4 Antibody Pact With BioNTech
2023-03-21
HHS Issues Initial Guidance on Negotiation Program as Government’s Latest Move to Reduce Drug Prices
2023-03-21
First-Ever Insect Brain Neuron Map Completed
2023-03-21
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
2023-03-20
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
2023-03-19
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
2023-03-19
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
2023-03-19
Scroll to Top